thumb
May 9, 2022

EISAI COMPLETES ROLLING SUBMISSION TO THE U.S. FDA FOR BIOLOGICS LICENSE APPLICATION OF LECANEMAB FOR EARLY ALZHEIMER’S DISEASE  UNDER THE ACCELERATED APPROVAL PATHWAY

TOKYO and CAMBRIDGE, Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that Eisai has completed the rolling submission to the U.S.

thumb
January 10, 2022

Biogen to Host Analyst Q&A Call

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will host an analyst Q&A call on Thursday, January 13, 2022, at 8:00 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at investors.biogen.com .

thumb
January 4, 2022

Biogen to Present at the 40th Annual J.P. Morgan Healthcare Conference

Cambridge, MA, - - Biogen Inc.  (Nasdaq: BIIB) announced today that it will present at the 40th Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 10, 2022, at 9:45 a.m. ET. To access the live webcast, please visit Biogen’s Investors section at

thumb
January 4, 2022

Biogen Exercises Option with Ionis to Develop and Commercialize Investigational ASO for SMA

BIIB115 is a preclinical investigational antisense oligonucleotide (ASO) that may have the potential for extended dosing intervals Biogen paid Ionis a $60 million one-time upfront payment CAMBRIDGE, Mass. and CARLSBAD, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Biogen Inc.

thumb
December 23, 2021

Investigational Alzheimer’s Disease Therapy Lecanemab Granted FDA Fast Track Designation

TOKYO and CAMBRIDGE, Mass, Dec. 23, 2021 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") announced today that lecanemab, an investigational anti-amyloid beta (Aβ)

thumb
December 22, 2021

Japan’s First Committee on New Drugs of The Pharmaceutical Affairs and Food Sanitation Council Seeks Additional Data; Aducanumab Remains under Review

CAMBRIDGE, Mass., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the First Committee on New Drugs (NDC) of the Pharmaceutical Affairs and Food Sanitation Council that advises the Ministry of Health, Labour and Welfare (MHLW) in

thumb
December 20, 2021

Biogen Announces Reduced Price for ADUHELM® to Improve Access for Patients with Early Alzheimer’s Disease

The company to also implement cost-reduction measures. CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that, effective January 1, 2022, it will reduce the wholesale acquisition cost (WAC) of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for

thumb
December 17, 2021

Update on Regulatory Submission for Aducanumab in the European Union

Biogen to seek re-examination following CHMP negative opinion for aducanumab CAMBRIDGE, Mass., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines

thumb
December 16, 2021

Update on the Phase 4 Confirmatory Study of ADUHELM®

CAMBRIDGE, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.  (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) today provided an important update on the continuing progress of the Phase 4 post-marketing confirmatory study of ADUHELM ® (aducanumab-avwa) 100 mg/mL injection for intravenous use in

thumb
December 14, 2021

Biogen and TheraPanacea Announce New Collaboration with the Potential to Advance Digital Health for Personalized Medicine in Neuroscience

Collaboration aims to develop innovative machine learning and artificial intelligence solutions for personalized and earlier treatment in neurology Biogen to gain exclusive rights to TheraPanacea technology in neuroscience CAMBRIDGE, Mass. and PARIS, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Biogen Inc.

thumb
December 1, 2021

Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD

In the zuranolone 50 mg cohort, the majority of patients who responded to an initial 14-day course received only one two-week course of treatment during the study and nearly 80% received only one or two treatment courses in total Zuranolone 50 mg was generally well-tolerated with an overall adverse